title: A pivotal role of endothelial-specific NF-kappaB signaling in the pathogenesis of septic shock and septic vascular dysfunction.
abstract: Although the role of NF-kappaB in the pathogenesis of sepsis and septic shock has been extensively studied, little is known about the causative contribution of endothelial-intrinsic NF-kappaB to these pathological processes. In this study, we used transgenic (TG) mice (on FVB genetic background) that conditionally overexpress the NF-kappaB inhibitor, mutant I-kappaBalpha, selectively on endothelium and their transgene-negative littermates (wild type (WT)) to define the causative role of endothelial-specific NF-kappaB signaling in septic shock and septic vascular dysfunction. In WT mice, LPS challenge caused systemic hypotension, a significantly blunted vasoconstrictor response to norepinephrine, and an impaired endothelium-dependent vasodilator response to acetylcholine, concomitant with a markedly increased aortic inducible NO synthase expression, significantly elevated plasma and aortic levels of nitrite/nitrate, increased aortic TNF-alpha expression, and decreased aortic endothelial NO synthase (eNOS) expression. In TG mice whose endothelial NF-kappaB was selectively blocked, LPS caused significantly less hypotension and no impairments in vasoconstrictor and endothelium-dependent vasodilator responses, associated with significantly reduced aortic inducible NO synthase expression, decreased plasma and aortic levels of nitrite/nitrate, reduced aortic TNF-alpha expression, and increased aortic eNOS expression. TNF-alpha knockout mice prevented LPS-induced eNOS down-regulation. WT mice subjected to cecal ligation and puncture showed significant systemic hypotension, which was prevented in TG mice. Our data show that selective blockade of endothelial-intrinsic NF-kappaB pathway is sufficient to abrogate the cascades of molecular events that lead to septic shock and septic vascular dysfunction, demonstrating a pivotal role of endothelial-specific NF-kappaB signaling in the pathogenesis of septic shock and septic vascular dysfunction.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Centers for Heart and Lung Research, and Immunology and Inflammation, Feinstein Institute for Medical Research, New Hyde Park, NY 11040, USA.
authors.forename: Jianqiang
authors.initials: J
authors.lastname: Ding
authors.forename: Dongmei
authors.initials: D
authors.lastname: Song
authors.forename: Xiaobing
authors.initials: X
authors.lastname: Ye
authors.forename: Shu Fang
authors.initials: SF
authors.lastname: Liu
mesh_terms: D000818:Animals; D004727:Endothelium / Q000378:metabolism*; D015870:Gene Expression; D006439:Hemodynamics / Q000187:drug effects; D020672:I-kappa B Proteins / Q000235:genetics; D008070:Lipopolysaccharides / Q000633:toxicity; D051379:Mice; D008822:Mice, Transgenic; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000235:genetics; D012772:Shock, Septic / Q000209:etiology*; D015398:Signal Transduction / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D014652:Vascular Diseases / Q000209:etiology*
chemical_list: D020672:I-kappa B Proteins; D008070:Lipopolysaccharides; D016328:NF-kappa B; C000606205:Nfkbia protein, mouse; D014409:Tumor Necrosis Factor-alpha; D000072000:NF-KappaB Inhibitor alpha; D019001:Nitric Oxide Synthase
references.citation: Shock. 2001 Nov;16(5):349-54
references.pmid: 11699072
references.citation: J Clin Invest. 2006 Nov;116(11):2955-63
references.pmid: 17053836
references.citation: Eur J Pharmacol. 1997 Aug 20;333(1):55-61
references.pmid: 9311661
references.citation: Am J Physiol Heart Circ Physiol. 2001 Nov;281(5):H1938-45
references.pmid: 11668054
references.citation: Circulation. 1999 Sep 21;100(12):1330-7
references.pmid: 10491379
references.citation: Blood. 2003 May 15;101(10):3765-77
references.pmid: 12543869
references.citation: Nature. 2007 Mar 29;446(7135):552-6
references.pmid: 17322906
references.citation: J Clin Invest. 2003 Aug;112(4):460-7
references.pmid: 12925683
references.citation: Am J Physiol. 1998 Feb;274(2):H564-70
references.pmid: 9486260
references.citation: J Immunol. 2007 May 15;178(10):6504-13
references.pmid: 17475880
references.citation: Circulation. 1992 Dec;86(6 Suppl):III12-19
references.pmid: 1424046
references.citation: Stroke. 2004 Aug;35(8):1963-7
references.pmid: 15218160
references.citation: J Biol Chem. 1999 Apr 9;274(15):9915-7
references.pmid: 10187764
references.citation: Circ Res. 2000 Apr 14;86(7):774-8
references.pmid: 10764411
references.citation: Circ Res. 2000 Sep 29;87(7):E18-24
references.pmid: 11009571
references.citation: Mol Pharmacol. 2002 May;61(5):953-63
references.pmid: 11961112
references.citation: Front Biosci. 2004 May 01;9:1201-17
references.pmid: 14977537
references.citation: Cardiovasc Res. 2002 Jun;54(3):684-93
references.pmid: 12031715
references.citation: Cell Metab. 2008 Nov;8(5):372-83
references.pmid: 19046569
references.citation: Nat Med. 2000 May;6(5):573-7
references.pmid: 10802715
references.citation: Circ Res. 2007 Aug 3;101(3):268-76
references.pmid: 17585070
references.citation: J Immunol. 1997 Oct 15;159(8):3976-83
references.pmid: 9378986
references.citation: J Immunol. 2001 Feb 1;166(3):2018-24
references.pmid: 11160251
references.citation: Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L622-L645
references.pmid: 16531564
references.citation: Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H962-8
references.pmid: 11179036
references.citation: J Biol Chem. 2004 Jan 9;279(2):963-9
references.pmid: 14581470
references.citation: Am J Physiol. 1998 Sep;275(3):H1078-83
references.pmid: 9724316
references.citation: Cell. 1995 Jan 27;80(2):321-30
references.pmid: 7834752
references.citation: J Biol Chem. 1999 Mar 19;274(12):7611-4
references.pmid: 10075645
references.citation: Circulation. 2000 Mar 7;101(9):1027-33
references.pmid: 10704171
references.citation: J Exp Med. 2008 Jun 9;205(6):1303-15
references.pmid: 18474628